glp 1 metabolism GLP-1 and Microbiome Repair for Long-Term Glucagon-like peptide-1: Trends in Endocrinology

In a recently completed phase 2 trial (abstract data), 46 weeks of survodutide once weekly (0.6 to 4.8 mg) resulted in a dose-dependent mean WL up to 18.7% vs

We now have multiple years of additional data, expanded FDA approvals, and a much clearer understanding that GLP-1 medications affect not only metabolism, but also the brain, behavior, and emotional experience

The primary completion date for this trial is slated for June of this year

Rajesh Aggarwal, an obesity doctor and founding CEO of twenty30 health a technology platform for individuals with obesity and metabolic disease described the world of GLP-1 compounding as a Wild West preying on desperate individuals. Dr